Stock Market & Financial Investment News: Educated Investors Get Live Stock Market News Feeds & Alerts at The Fly On the Wall

News For NVO;VPHM;INFI;MRK;AGN;SHPG;SGEN;OREX;AMGN;SNY;JNJ;PFE From The Last 14 Days Check below for free stories on NVO;VPHM;INFI;MRK;AGN;SHPG;SGEN;OREX;AMGN;SNY;JNJ;PFE the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 \| 2 \| 3 \| 4 \| 5 \| all recent news \| >>
June 19, 2013
17:52 EDT	PFE	Pfizer announces final exchange ratio for Zoetis exchange offer Subscribe for More Information

16:01 EDT	PFE	Options Update; June 19, 2013 Subscribe for More Information

13:53 EDT	SNY	Sanofi to hold a conference call Subscribe for More Information

13:50 EDT	JNJ	J&J issued FDA warning letter on Xarelto advertising Subscribe for More Information

12:22 EDT	OREX	Outlook for obesity drug coverage has improved, says Leerink Leerink notes that the VA started covering Vivus' (VVUS) Qsymia in April, while a bipartisan group of lawmakers will introduce a bill today to make Medicare begin covering weight-loss drugs. Meanwhile the AMA has labeled obesity a disease for the first time, Leerink added. The firm believes that the community will begin treating obesity as a disease, and it thinks that recent events could enable weight loss drug makers to exceed its estimates. The firm reiterates Outperform ratings on weight loss drug makers Vivus, Arena (ARNA), and Orexigen (OREX).

10:30 EDT	PFE	Pfizer management to meet with ISI Group Subscribe for More Information

10:01 EDT	NVO	On The Fly: Analyst Downgrade Summary Subscribe for More Information

09:49 EDT	OREX	Weight loss drug makers rise after AMA calls obesity a disease Makers of anti-obesity drugs are advancing after the American Medical Association designated obesity as a disease. WHAT'S NEW: The AMA recognized obesity as a disease yesterday. Obesity "requires a range of medical interventions," and the treatment and prevention of the condition must be advanced, the organization stated. The AMA's decision will help change the way doctors deal with obesity, AMA board member Patrice Harris, M.D, stated. TODAY'S PRICE ACTION: In early trading, Arena Pharmaceuticals (ARNA) rose 2% to $7.65, while VIVUS (VVUS) climbed 2.4% to $14.10 and Orexigen (OREX) inched up 0.3% to $6.40.

09:38 EDT	MRK	Active equity option families trading on open Active equity option families trading on open according to Track Data: AAPL AMAT FDX MA C GOOG DISH AMRN MRK BIDU

09:05 EDT	SGEN	Seattle Genetics, Takeda announce data from analysis of PFS with ADCETRIS Takeda Pharmaceutical and Seattle Genetics announced data from a post-hoc analysis examining progression-free survival, PFS, following treatment with ADCETRIS versus last prior therapy in patients diagnosed with relapsed or refractory Hodgkin lymphoma post-autologous stem cell transplant or relapsed or refractory systemic anaplastic large cell lymphoma. The data were highlighted during a presentation at the 12th International Conference on Malignant Lymphoma being held June 19–22, 2013 in Lugano, Switzerland. The post-hoc analysis compared investigator assessed PFS following ADCETRIS single-agent treatment to the last prior systemic therapy in patients taking part in two pivotal Phase 2 studies. “These encouraging data suggest that ADCETRIS may delay disease progression compared to prior therapies used in this heavily pretreated patient population,” said John Radford, M.D., Professor of Medical Oncology, University of Manchester, Manchester, UK. “ADCETRIS is a CD30-targeted treatment option for patients with relapsed or refractory HL or relapsed or refractory sALCL that has shown a high overall response rate, including durable complete responses in both of its approved indications.”

08:45 EDT	JNJ	Leerink's biotech analyst holds analyst/industry conference call on ADA Analyst Antlaffy, along with Dr. George Grunberger, founder & Chairman of the Grunberger Diabetes Institute, preview the upcoming American Diabetes Association's conference, including perspectives on new devices in diabetes, potential disruptive technologies at ADA and progress towards the artificial pancreas on an Analyst/Industry conference call to be held on June 20 at 2 pm.

07:41 EDT	PFE	Pfizer holders should consider Zoetis exchange, says BMO Capital BMO Capital thinks Pfizer (PFE) investors should consider participating in the Zoetis (ZTS) exchange as they have the opportunity to own Zoetis at around $29.40-$29.70 per share, which is 15% below BMO's valuation of $34 per share. Further, BMO thinks there is strong support for Zoetis below $30, which the firm feels lowers downside risk. BMO recommends that Pfizer investors tender around 20% of their shares into the exchange, noting that with the offer likely being oversubscribed, not all tendered shares will be converted to Zoetis.

06:52 EDT	OREX	AMA recognizes obesity as disease. NY Times reports The American Medical Association, or AMA, has officially recognized obesity as a disease, The New York Times reported yesterday. The decision could cause more insurance companies to pay for obesity treatments and spur more doctors to take more steps to combat the condition, the newspaper stated. The AMA overrode a recommendation by a committee that had recommended against making the change, the newspaper noted. Reference Link

05:44 EDT	NVO	Novo Nordisk downgraded to Underperform from Neutral at Exane BNP Paribas Subscribe for More Information

June 18, 2013
19:07 EDT	AMGN	On The Fly: After Hours Movers Subscribe for More Information

17:25 EDT	AMGN	Amgen reports 7.58% stake in Cytokinetics Subscribe for More Information

16:00 EDT	MRK	Options Update; June 18, 2013 Subscribe for More Information

15:15 EDT	NVO	Novo Nordisk says court rules against company in patent litigation Subscribe for More Information

11:20 EDT	INFI	Infinity Pharmaceuticals shares up 11%, or $1.97, to $19.14 Subscribe for More Information

09:38 EDT	PFE	Active equity option families trading on open Active equity option families trading on open according to Track Data: AAPL NFLX GOOG PFE TSLA MGM

09:04 EDT	AGN	Wells Faro to host a conference 2013 Healthcare Conference is being held in Boston on June 18-19 with webcasted company presentations to begin at 8:15 am; not all company presentations may be webcasted. Webcast Link

08:38 EDT	SNY	Sanofi management to meet with JPMorgan Subscribe for More Information

08:37 EDT	MRK	Drug companies turn to microchips to test medicines, WSJ reports Subscribe for More Information

08:36 EDT	AGN	Elan shares could be worh $19 in a buyout, says Jefferies Jefferies raised its price target for shares of Elan (ELN) to $19 from $14, reflecting what it sees as the value of the company in a takeout scenario. The firm says Elan management suggested they would be open to sale in the $15-$20 per share range. Jefferies believes a high taxpaying suitor could pay the upper end of that range, and lists Allergan (AGN), Regeneron (REGN), Vertex (VRTX), Alexion (ALXN), Zoetis (ZTS), Mylan (MYL) and Perrigo (PRGO) as potential acquirers for Elan. Shares of Elan are up 13c to $13.62 in pre-market trading after Royalty Pharma announced that its buyout proposal for the company has expired.

07:34 EDT	JNJ	Medivation pullback a buying opportunity, says JPMorgan Subscribe for More Information

07:28 EDT	AGN	Wells Faro to host a conference Subscribe for More Information

07:22 EDT	SHPG	Citigroup to host a conference Subscribe for More Information

June 17, 2013
16:20 EDT	VPHM, JNJ	On The Fly: Closing Wrap Stocks on Wall Street were higher following a session dominated by speculation over what is next for the Federal Reserve. The averages trimmed their gains after an article by the Financial Times suggested the Fed would signal a tapering of its pace of asset purchases at its Wednesday press conference. The upward trend resumed after the article's author said the report was based on opinion and that, "The Fed does not leak anything to any journalist to steer markets - especially during blackout." ECONOMIC EVENTS: In the U.S., the New York Fed Empire State Survey for June came in at 7.40, versus expectations for a 0 reading. The NAHB housing market confidence index for June rose to 52, versus the forecast for a more modest climb to 45 from its prior 44 reading. In Europe, Germany's Bundesbank said economic indicators for April pointed to robust growth in the second quarter and business sentiment improved in May, though warned of signs that growth in Europe's largest economy would slow over the summer. COMPANY NEWS: Netflix (NFLX) and DreamWorks (DWA) both climbed after announcing a major content deal. Under the agreement, DreamWorks will provide over 300 hours of content to Netflix, which the TV and movie service expects to start broadcasting next year. After the announcement, Netflix rose $15.24, or 7.12%, to $229.23, while DreamWorks added 93c, or 4.08%, to $23.74. MAJOR MOVERS: Among the notable gainers was Kandi Technologies (KNDI), up $1.53, or 24.4%, to $7.80 after saying it will deploy 5K-10K pure electric vehicles in China within the first year of launch. Also higher were shares of ViroPharma (VPHM), up $1.71, or 6.3%, to $28.87 after Reuters said the company has attracted takeover interest, though the company is not pursuing a sale. Among the noteworthy losers was Terex (TEX), down $2.45, or 7.72%, to $29.29 after the company lowered it fiscal year earnings view. Also lower was Medivation (MDVN), down $3.45, or 6.78%, to $47.41 after Johnson & Johnson (JNJ) acquired the company's competitor, privately held Aragon Pharmaceuticals. INDICES: The Dow was up 109.67, or 0.73%, to 15,179.85; the Nasdaq was up 28.57, or 0.83%, to 3,452.13; and the S&P 500 was up 12.31, or 0.76%, to 1,639.04.

16:00 EDT	PFE	Options Update; June 17, 2013 Subscribe for More Information

13:40 EDT	VPHM	ViroPharma June calls active on attracting takeover interest ViroPharma June 30 calls are active on total call volume of 1,900 contracts (210 puts). June call option implied volatility is at 58, July and August is at 48, November is at 39; above its 26-week average of 37 according to Track Data, suggesting larger price movement on the company not pursuing a sale but attracting takeover interest, Reuters says.

12:29 EDT	JNJ	On The Fly: Midday Wrap Subscribe for More Information

12:28 EDT	JNJ	Medivation retreats after J&J beefs up prostate cancer slate Subscribe for More Information

12:08 EDT	JNJ	J&J deal not negative for Medivation, says Citigroup Subscribe for More Information

11:55 EDT	SHPG	High option volume stocks: SPHG CSIQ TS GAME CRZO Subscribe for More Information

11:37 EDT	VPHM	ViroPharma not pursuing sale but attracting takeover interest, Reuters says Subscribe for More Information

11:34 EDT	VPHM	ViroPharma up 9% after Reuters report of takeover interest Subscribe for More Information

11:33 EDT	VPHM	ViroPharma has attracted preliminary takeover interest, Reuters reports Subscribe for More Information

10:10 EDT	NVO	On The Fly: Analyst Downgrade Summary Subscribe for More Information

08:36 EDT	PFE, MRK	InSite Vision to join Merck, Pfizer patent suit against Mylan InSite Vision (INSV) announced that it will join Merck (MRK) and Pfizer (PFE) in filing a patent infringement lawsuit against Mylan Pharmaceuticals (MYL). Mylan recently filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking to market a generic version of AzaSite before expiration of the patents covering AzaSite and its use. AzaSite is marketed by Merck in the U.S. On May 26, 2011, InSite and Merck filed a similar patent infringement lawsuit against Sandoz. A trial date for the Sandoz ANDA suit has been set for July 11, 2013. The companies have agreed that Merck will take the lead in prosecuting both lawsuits. Each company will be responsible for their own legal costs, with InSite assuming a monitoring role, the company said.

08:04 EDT	JNJ	Johnson & Johnson agrees to acquire Aragon Pharmaceuticals Johnson & Johnson announced a definitive agreement to acquire Aragon Pharmaceuticals, a privately-held, pharmaceutical discovery and development company focused on drugs to treat hormonally-driven cancers. The acquisition includes Aragon's androgen receptor antagonist program. Aragon's lead product candidate is a second generation androgen receptor signaling inhibitor, ARN-509, in Phase 2 development for castration resistant prostate cancer. Under the terms of the agreement, Johnson & Johnson will make an upfront cash payment of $650M, plus additional contingent payments of up to $350M based on reaching predetermined milestones. The transaction is expected to close in the third quarter of 2013.

07:28 EDT	PFE	Cambridge Healthtech Institute to host a conference Subscribe for More Information

07:28 EDT	NVO	Novo Nordisk downgraded at BofA/Merrill Subscribe for More Information

07:25 EDT	SHPG	Leerink to host a conference Subscribe for More Information

06:43 EDT	NVO	Novo Nordisk downgraded to Neutral from Buy at BofA/Merrill

June 16, 2013
14:45 EDT	JNJ	J&J's Depuy Synthes unit wins $16M in patent case, Bloomberg says Subscribe for More Information

11:44 EDT	AMGN	Amgen still looks attractive, Barron's says Subscribe for More Information

June 14, 2013
17:15 EDT	MRK	Merck cutting layer of R&D management, WSJ reports Merck is planning to cut jobs and strip a level of senior management from its R&D unit, reports The Wall Street Journal. Reference Link

16:00 EDT	PFE	Options Update; June 14, 2013 Subscribe for More Information

15:49 EDT	JNJ	J&J's Mentor gets FDA approval for MemoryShape breast implants Mentor Worldwide announced earlier the U.S. Food and Drug Administration has approved MENTOR MemoryShape breast implants. The open-label, multi-center MENTOR MemoryShape Breast Implant Core Study showed the implants were safe and effective in both reconstruction and augmentation patients at 6 years, with a low rate of adverse events, such as rupture and capsular contracture Baker grades III and IV. Post approval studies will be conducted to collect additional clinical data for the MemoryShape implants. Mentor joined the Johnson & Johnson family of companies in 2009 and is part of its Global Surgery Group.

13:21 EDT	MRK	Merck to cut jobs, restructure R&D unit, Dow Jones reports

06:45 EDT	PFE	Zoetis volatility elevated into Pfizer split-off Subscribe for More Information

June 13, 2013
17:39 EDT	JNJ	J&J files to sell 25.38M shares of Elan Subscribe for More Information

16:00 EDT	PFE	Options Update; June 13, 2013 Subscribe for More Information

11:06 EDT	AMGN	FDA approves Xgeva to treat giant cell tumor of the bone Subscribe for More Information

11:04 EDT	AMGN	FDA approves Xgeva to treat giant cell tumor of the bone Subscribe for More Information

11:02 EDT	SNY, JNJ	Leerink's major pharma analyst holds an analyst/Industry conference call Subscribe for More Information

08:24 EDT	JNJ	J&J unit says data show Stelara improved components of psoriatic arthritis Janssen Research & Development, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced that results from a Phase 3 study published in The Lancet showed patients with active psoriatic arthritis who received either STELARA 45 mg or 90 mg achieved significant improvement in joint symptoms at the study's primary endpoint compared with patients receiving placebo. According to findings from the investigational study, continued treatment with STELARA every 12 weeks resulted in improvements in signs and symptoms of active disease and psoriasis symptoms through one year. In December 2012, Janssen announced submissions to health authorities in the U.S. and Europe seeking approval of STELARA for the treatment of active psoriatic arthritis. STELARA is approved for the treatment of adults with moderate to severe plaque psoriasis in 72 countries.

07:32 EDT	PFE, AMGN	European League Against Rheumatism to host annual meeting Subscribe for More Information

June 12, 2013
17:56 EDT	JNJ	Johnson & Johnson's Cordis receives FDA clearance for Adroit catheter Subscribe for More Information

16:02 EDT	MRK, PFE	Options Update; June 12, 2013 Subscribe for More Information

13:31 EDT	PFE	Mylan could be interested in generic assets split from Pfizer, Bloomberg says

10:35 EDT	MRK	Merck management to meet with ISI Group Subscribe for More Information

09:13 EDT	AMGN	Amgen, AstraZeneca to advance brodalumab into Phase 3 studies Subscribe for More Information

09:04 EDT	AMGN	Amgen announces positive top-line results of Phase 3 trebananib Subscribe for More Information

08:28 EDT	PFE	Teva to pay $1.6B to settle with Pfizer, Nycomed over generic Protonix Subscribe for More Information

08:04 EDT	MRK	Merck says independent review of JANUVIA safety profile 'welcomed' Subscribe for More Information

08:02 EDT	PFE	Pfizer wins $2.15B settlement from Teva and Sun for patent infringement Subscribe for More Information

07:39 EDT	AMGN	Amgen, Cytokinetics announce expansion of license for omecamtiv mecarbil Subscribe for More Information

June 11, 2013
16:00 EDT	PFE	Options Update; June 11, 2013 Subscribe for More Information

15:15 EDT	PFE	Pfizer June volatility at one-year high Subscribe for More Information

13:09 EDT	AGN	Allergan has a conference call hosted by BMO Capital Subscribe for More Information

10:56 EDT	JNJ	AstraZeneca to bid for Israeli biotech incubator, Globes reports Subscribe for More Information

08:01 EDT	MRK	Leerink's major pharma and biotech analysts hold a conference call Subscribe for More Information

07:42 EDT	PFE, MRK	Boston Biotech Conferences to host a conference Subscribe for More Information

07:31 EDT	AMGN	Goldman to host a conference Subscribe for More Information

06:20 EDT	VPHM	ViroPharma receives Orphan drug designation for Maribavir in Europe Subscribe for More Information

06:08 EDT	INFI	Stocks with implied volatility below IV index mean; MBI INFI Stocks with implied volatility below IV index mean; MBIA (MBI), Infinity Pharmaceuticals (INFI) according to IVolatility.

June 10, 2013
11:41 EDT	MRK	Merck loss in Nasonex patent fight upheld on appeal Merck Sharp & Dohme, formerly known as Schering, appealed a lower court ruling in favor of Apotex. Reference Link

11:40 EDT	INFI	Options with decreasing implied volatility: TIVO INFI NBG UNXL FRAN

09:19 EDT	SGEN	Seattle Genetics announces start of Hodgkin Lymphoma treatment phase 1/2 trial Seattle Genetics announced the initiation of a phase 1/2 clinical trial evaluating Adcentris in combination with bendamustine for patients with Hodgkin lymphoma after first relapse. The multi-phase study is divided into two cohorts to determine the recommended dosing level and tolerability of combination use and to assess the complete remission rate associated with Adcentris in combination with bendamustine. Of the 14 evaluable patients, 12 patients had an objective response rate, including seven complete remissions and five partial remissions. The most common Grade 1 or 2 adverse events were peripheral sensory neuropathy, acneiform rash, AST elevation, and fatigue. Grade 3 adverse events were rash acneiform and urinary tract infection and there were no Grade 4 adverse events.

07:40 EDT	SGEN, AMGN, JNJ, PFE, INFI	Leerink's biotech analyst holds analyst/industry conference call on ASCO Subscribe for More Information

07:20 EDT	AMGN, PFE, SNY, JNJ	Biomed to host a conference Subscribe for More Information

07:19 EDT	INFI	Infinity Pharmaceuticals weakness an overreaction, says Stifel After meeting with Infinity's management, Stifel views weakness in the shares following ASCO data as an overreaction. The firm thinks that the ASCO data reaffirmed that IPI-145 is an active drug in iNHL and CLL, and it views the drug as competitive with other hematological malignancy drugs that are being developed. The firm keeps a Buy rating on the stock.

07:10 EDT	SHPG	Shire price target raised to $115 from $101-$102 at Leerink Subscribe for More Information

07:03 EDT	SNY	Sanofi announces FDA approved sBLA for licensure of influenza vaccine Subscribe for More Information

06:38 EDT	INFI	Stocks with implied volatility below IV index mean; MBI INFI Stocks with implied volatility below IV index mean; MBIA (MBI), Infinity Pharmaceuticals (INFI) according to IVolatility.

June 7, 2013
11:56 EDT	INFI	Options with decreasing implied volatility: TIVO INFI NBG UNXL Subscribe for More Information

06:00 EDT	INFI	Stocks with implied volatility below IV index mean; CSCO INFI Subscribe for More Information

June 6, 2013
16:01 EDT	MRK	Options Update; June 6, 2013 CBOE Volatility Index VIX down 72c to 16.78. Option volume leaders: AAPL TSLA GOOG C MRK BAC according to Track Data.

12:04 EDT	INFI	Options with decreasing implied volatility: INFI FRAN GES ANN OVTI

06:16 EDT	INFI	Stocks with implied volatility below IV index mean; NBG INFY Subscribe for More Information

<< 1 \| 2 \| 3 \| 4 \| 5 \| all recent news \| >> Sign up for a free trial to see the rest of the stories you've been missing.